WAKE-UP
2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
In 503 patients with ischaemic stroke of unknown onset and DWI–FLAIR mismatch, alteplase improved mRS 0–1 at 90 days versus placebo.
Result
Efficacy: mRS 0–1 at 90 daysadj. OR 1.61 (95% CI 1.09-2.36) · P = 0.02
Below 1 favours placebo, above 1 favours alteplase.
- Absolute difference
- 11.5 points
- NNT
- 9
Absolute difference and NNT are derived from the event rates.
Also reported: Numerically higher mortality with alteplase.
- Subtopic
- MRI-guided lysis
- Design
- Double-blind RCT; stopped early due to funding
- Relevance
- Important: one of several pillars.
- Cited in
- AHA/ASA 2026 Stroke
- Source
- Thomalla G, et al. N Engl J Med. 2018;379(7):611-622.doi 10.1056/NEJMoa1804355
Discussion & critique
Enables MRI-selected thrombolysis in wake-up stroke.